# Amolyt Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amolyt-pharma

- Industry: Biotechnology
- Headquarters: France
- Website: www.amolytpharma.com
- Total disclosed funding: $228M
- Latest round: Series C (Jan 6, 2023)
- Investors on record: 20

## About

Based in Ecully, France, and founded in 2015, Amolyt Pharma SAS, operates as a biotechnology company that develops and provides therapeutic peptides for patients with rare endocrine and metabolic diseases. In January 2023, Amolyt Pharma SAS raised EUR 130 million in Series C funding co-led by Intermediate Capital Group and Sofinnova Partners. Further, in March 2024, Amolyt Pharma SAS was acquired by AstraZeneca's Cardiovascular Medicine agreed to an upfront payment of USD 800 million, and will receive approximately USD 250 million upon achieving milestones through 2024. The firm, as of July 2024, has offices in France and the US and is led by its founder and CEO, Thierry Abribat.

The clinical-stage global biotechnology company's pipeline focuses on two lead programs. Eneboparatide, a therapeutic peptide, is being developed for hypoparathyroidism, aiming to offer superior clinical benefits compared to existing treatments. AZP-3813, which targets acromegaly with its potent growth hormone receptor antagonist properties. Another program of the firm is AZP-40XX, which is a select group of monoclonal antibodies targeting the parathyroid receptor 1 for Primary Hyperparathyroidism (PHPT) and Humoral Hypercalcemia of Malignancy (HHM).

## Funding rounds

- Series C, Jan 6, 2023, $138M — Intermediate Capital Group, OrbiMed Advisors, Sofinnova Partners, Andera Partners, EQT Life Sciences, Novo Holdings, Turenne Groupe, CTI Life Sciences, Tekla Capital Management, Bpifrance Investissement Régions, Pontifax Venture Capital, Kurma Partners, Mass General Brigham Ventures, Sectoral Asset Management, ATEM Capital, Credit Agricole Creation
- Series B, Sep 16, 2021, $53M — OrbiMed Advisors, Andera Partners, EQT Life Sciences, Eurazeo, Novo Holdings, Turenne Groupe, Pontifax Venture Capital, Kurma Partners, Mass General Brigham Ventures, Sectoral Asset Management, Bpifrance Investissement, Crédit Agricole Alpes Développement, ATEM Capital, TAB Consulting
- Series A, Oct 4, 2019, $37M — OrbiMed Advisors, EQT Life Sciences, Novo Holdings, Turenne Groupe, Pontifax Venture Capital, Kurma Partners, Mass General Brigham Ventures, Bpifrance Investissement, Crédit Agricole Alpes Développement, TAB Consulting

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C
- Novo Holdings — Series A, Series B, Series C
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series A, Series B, Series C
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B, Series C
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B, Series C
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B, Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- Crédit Agricole Alpes Développement (https://capitalatlas.ai/funds/credit-agricole-alpes-developpement) — Series A, Series B
- TAB Consulting — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B, Series C
- ATEM Capital (https://capitalatlas.ai/funds/atem-capital) — Series B, Series C
- Intermediate Capital Group — Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series C
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Bpifrance Investissement Régions (https://capitalatlas.ai/funds/bpifrance-investissement-regions) — Series C
- Credit Agricole Creation (https://capitalatlas.ai/funds/credit-agricole-creation) — Series C